ATE515506T1 - Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren - Google Patents

Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren

Info

Publication number
ATE515506T1
ATE515506T1 AT08708929T AT08708929T ATE515506T1 AT E515506 T1 ATE515506 T1 AT E515506T1 AT 08708929 T AT08708929 T AT 08708929T AT 08708929 T AT08708929 T AT 08708929T AT E515506 T1 ATE515506 T1 AT E515506T1
Authority
AT
Austria
Prior art keywords
synthesis
kinase inhibitors
aminothiazole compounds
aminothiazole
compounds
Prior art date
Application number
AT08708929T
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
Francois Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Application granted granted Critical
Publication of ATE515506T1 publication Critical patent/ATE515506T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT08708929T 2007-02-13 2008-02-13 Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren ATE515506T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE515506T1 true ATE515506T1 (de) 2011-07-15

Family

ID=39332208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08708929T ATE515506T1 (de) 2007-02-13 2008-02-13 Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren

Country Status (23)

Country Link
US (3) US8153792B2 (de)
EP (2) EP2118099B1 (de)
JP (2) JP5568312B2 (de)
KR (1) KR20090110851A (de)
CN (2) CN103342701B (de)
AR (1) AR065337A1 (de)
AT (1) ATE515506T1 (de)
AU (1) AU2008214679A1 (de)
BR (1) BRPI0807626B1 (de)
CA (2) CA2677586C (de)
ES (2) ES2369617T3 (de)
HR (2) HRP20110709T1 (de)
IL (1) IL200320A0 (de)
MA (1) MA31180B1 (de)
MX (1) MX2009008665A (de)
NZ (1) NZ578944A (de)
PL (2) PL2118099T3 (de)
RU (2) RU2456285C2 (de)
SI (2) SI2366703T1 (de)
TN (1) TN2009000342A1 (de)
TW (1) TWI406862B (de)
WO (1) WO2008098949A2 (de)
ZA (1) ZA200905981B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
AR080048A1 (es) 2010-01-28 2012-03-07 Ab Science Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib
WO2011092338A1 (en) 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
WO2011151372A1 (en) 2010-06-02 2011-12-08 Ab Science Treatment of rheumatoid arthritis with masitinib
US20140147415A1 (en) 2010-11-05 2014-05-29 Ab Science Treatment of mastocytosis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
AR085934A1 (es) 2011-04-08 2013-11-06 Ab Science Tratamiento de mieloma multiple con masitinib
US10238649B2 (en) 2012-10-04 2019-03-26 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
WO2015082496A1 (en) 2013-12-02 2015-06-11 Ab Science Use of masitinib for treatment of colorectal cancer
EP2886543A1 (de) 2013-12-18 2015-06-24 Sandoz Ag Kristalline Form von Masitinib
US20170196853A1 (en) 2014-06-02 2017-07-13 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
WO2017016512A1 (zh) * 2015-07-29 2017-02-02 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
EP3359195B1 (de) 2015-10-05 2024-05-29 AB Science Behandlung schwerer systemischer mastozytose mit masitinib
SG11201808106YA (en) 2016-03-25 2018-10-30 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2018177854A1 (en) 2017-03-31 2018-10-04 Sandoz Ag Crystalline form of masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2021099616A1 (en) 2019-11-22 2021-05-27 Ab Science Masitinib for the treatment of sickle cell disease
EP3831384A1 (de) 2019-12-02 2021-06-09 AB Science Verwendung von masitinib zur behandlung von eosinophilem asthma
CN115515590A (zh) 2020-02-20 2022-12-23 Ab科学有限公司 马赛替尼用于治疗多发性硬化患者亚群
CN115867278B (zh) 2020-04-10 2025-02-28 Ab科学有限公司 马赛替尼用于治疗covid-19的用途
US20240058328A1 (en) 2020-12-16 2024-02-22 Ab Science Masitinib for the treatment of alzheimer's disease
MX2023013781A (es) 2021-05-17 2023-12-04 Ab Science Masitinib para el tratamiento del cancer de prostata resistente a la castracion.
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
PL342447A1 (en) * 1997-10-27 2001-06-04 Agouron Pharma Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
AU779908B2 (en) * 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003002109A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
EP1401429A2 (de) 2001-06-29 2004-03-31 AB Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von mastocysosis
WO2003003006A2 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004537542A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
US20040266797A1 (en) 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
EP1401411A2 (de) 2001-06-29 2004-03-31 AB Science Verwendung von tyrosin kinase hemmern zur behandlung von knochenschwund
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
US20040259892A1 (en) 2001-06-29 2004-12-23 Alain Moussy Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
EP1461032B1 (de) 2001-09-20 2008-07-16 AB Science Die verwendung von c-kithemmern zur förderung des haarwuchses
ATE388711T1 (de) 2001-09-20 2008-03-15 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
EP1427422A1 (de) 2001-09-20 2004-06-16 AB Science Verwendung von tyrosinkinase-hemmern zur aufhellung menschlicher haut und zur behandlung von krankheiten im zusammenhang mit einer melanozytenfehlfunktion
DE60307237T2 (de) 2002-02-27 2007-10-18 Ab Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
EP1490067B1 (de) 2002-02-27 2008-09-17 AB Science Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
MXPA04011579A (es) * 2002-05-29 2005-03-07 Amgen Inc Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular.
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
JP2006517234A (ja) * 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
CA2517308A1 (en) 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
ATE395052T1 (de) 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
BRPI0418074B8 (pt) 2003-12-25 2021-05-25 Nippon Shinyaku Co Ltd derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
KR20090110851A (ko) 2009-10-22
US8492545B2 (en) 2013-07-23
US8940894B2 (en) 2015-01-27
CA2970628C (en) 2019-08-27
EP2118099B1 (de) 2011-07-06
PL2118099T3 (pl) 2011-12-30
CA2677586C (en) 2017-07-25
NZ578944A (en) 2011-03-31
CA2970628A1 (en) 2008-08-21
EP2366703A1 (de) 2011-09-21
ES2522169T3 (es) 2014-11-13
CN103342701A (zh) 2013-10-09
EP2118099A2 (de) 2009-11-18
RU2009132186A (ru) 2011-03-20
MX2009008665A (es) 2009-08-21
RU2456285C2 (ru) 2012-07-20
JP5784073B2 (ja) 2015-09-24
US20120196871A1 (en) 2012-08-02
CN101657446A (zh) 2010-02-24
ZA200905981B (en) 2010-11-24
SI2366703T1 (sl) 2014-10-30
HRP20110709T1 (hr) 2011-11-30
IL200320A0 (en) 2010-04-29
SI2118099T1 (sl) 2011-11-30
WO2008098949A2 (en) 2008-08-21
JP2010518141A (ja) 2010-05-27
BRPI0807626B1 (pt) 2022-03-03
JP5568312B2 (ja) 2014-08-06
EP2366703B1 (de) 2014-07-30
WO2008098949A3 (en) 2008-10-02
CN103342701B (zh) 2016-09-21
BRPI0807626A2 (pt) 2014-11-25
US8153792B2 (en) 2012-04-10
PL2366703T3 (pl) 2015-02-27
TW200848419A (en) 2008-12-16
TWI406862B (zh) 2013-09-01
HRP20140986T1 (hr) 2014-11-21
ES2369617T3 (es) 2011-12-02
AR065337A1 (es) 2009-06-03
AU2008214679A1 (en) 2008-08-21
RU2491286C1 (ru) 2013-08-27
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
US20130289045A1 (en) 2013-10-31
TN2009000342A1 (en) 2010-12-31
CA2677586A1 (en) 2008-08-21
CN101657446B (zh) 2013-05-15
JP2013177437A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
ATE515506T1 (de) Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren
ATE538111T1 (de) Verfahren zur synthese von 5- alkoxymethylfurfuralethern
ATE474845T1 (de) Verfahren zur synthese von saccharose-6-estern
ATE459416T1 (de) Verfahren zur beseitigung von endokrin wirksamen verbindungen
ATE540931T1 (de) Verfahren zur synthese organischer verbindungen
DE602008004764D1 (de) Verfahren zur hydrokonversion von schwerölen
CY2017042I2 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
SMT201600267B (it) Inibitori di syk imidazopirazinici
PL2021335T3 (pl) Związki heterocykliczne jako inhibitory kinazy C-FMS
ATE554078T1 (de) Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
ATE551342T1 (de) Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
SI3354650T1 (sl) Spojine, uporabne kot zaviralci ATR kinaze
ZA201103411B (en) Compounds useful as inhibitors of atr kinase
EP1973497A4 (de) Verfahren zur schnellen reparatur von körperleitungen
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK2257532T3 (da) Fremgangsmåde til regioselektiv syntese af 1-alkyl-3-haloalkyl-pyrazol-4-carboxylsyrederivater
EP2323659A4 (de) Als proteinkinasehemmer nützliche verbindungen
DE602007008201D1 (de) Verfahren zur qualitätskontrolle von speichermedien
ATE460408T1 (de) Verfahren zur synthese von strontiumranelat und seinen hydraten
DE602006014670D1 (de) Verfahren zur doppelbindungs-hydroisomerisierung von butenen
ATE487709T1 (de) Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)benzolamin
DE112009001327A5 (de) Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen
DE112008002579A5 (de) Verfahren zur Synthese von A-Ring-Aromatisierten Acetyl-Minocyclinen
EP2061492A4 (de) Verfahren zur linderung von schmerzen durch modifikation von nmda-rezeptoren durch hemmung von src
ATE425159T1 (de) Substituierte 4-phenylpiperidine zur verwendung als renininhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties